The Cancer Symptoms Partnering 2010-2015 report provides understanding and access to the Cancer symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in cancer symptoms partnering deals
- Top cancer symptoms deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type
The Cancer Symptoms Partnering 2010-2015 provides understanding and access to the Cancer symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.
This report provides details of the latest cancer symptoms agreements announced in the healthcare sectors, covering:
- Oral mucositis
- Cancer pain
- Weight Loss
The report provides an analysis of cancer symptoms partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors cancer symptoms technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 100 links to online copies of actual cancer symptoms deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of cancer symptoms partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.
Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.
Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.
Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer symptoms technologies and products.
Cancer Symptoms Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to cancer symptoms trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in cancer symptoms dealmaking in the biopharma industry since 2010
- Access to summary headline, upfront, milestone and royalty data
- Access to over 100 cancer symptoms deals and contract documents where available
- The leading cancer symptoms deals by value since 2010
In Cancer Symptoms Partnering 2010-2015, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Table of Content
Chapter 1 – Introduction
Chapter 2 – Trends in cancer symptoms partnering
2.2. Cancer symptoms partnering over the years
2.3. Cancer symptoms partnering by deal type
2.4. Cancer symptoms partnering industry sector
2.5. Cancer symptoms partnering by stage of development
2.6. Cancer symptoms partnering by technology type
Chapter 3 – Average deal terms for Cancer symptoms
3.2 Average deal terms for Cancer symptoms
3.3 Cancer symptoms headline values with median calculation
3.4 Cancer symptoms upfront values with median calculation
3.5 Cancer symptoms milestone values with median calculation
3.6 Cancer symptoms royalty rates with median calculation
Chapter 4 – Active cancer symptoms dealmakers
4.2 Most active Cancer symptoms dealmakers
4.3. Top Cancer symptoms deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity
Chapter 5 – Cancer symptoms dealmaking directory
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type
Chapter 6 – Partnering resource center
6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking
Appendix 1 – Deal type definitions
About Wildwood Ventures
Recent report titles from Current Partnering
Order Form – Reports
Order Form – Subscription Access Products
Figure 1: Cancer symptoms partnering since 2010
Figure 2: Cancer symptoms dealmaking activity– 2010 to 2015
Figure 3: Cancer symptoms partnering by deal type since 2010
Figure 4: Cancer symptoms partnering by industry sector since 2010
Figure 5: Cancer symptoms partnering by stage of development since 2010
Figure 6: Cancer symptoms partnering by technology type since 2010
Figure 7: Cancer symptoms deals with a headline value
Figure 8: Cancer symptoms deals with upfront payment values
Figure 9: Cancer symptoms deals with milestone payments
Figure 10: Cancer symptoms deals with royalty rates, %
Figure 11: Top Cancer symptoms deals by value since 2010
Figure 12: Big pharma – top 50 – Cancer symptoms deals 2010 to 2015
Figure 13: Big pharma Cancer symptoms deal frequency – 2010 to 2015
Figure 14: Big biotech – top 50 – Cancer symptoms deals 2010 to 2015
Figure 15: Big biotech Cancer symptoms deal frequency – 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions